Code |
Diagnosis |
Comment |
Score |
anonymous |
Low grade lymphoma infiltrate
|
CD3, L26, MPO immunostains
|
70 |
anonymous |
lymphoma
|
perform immunostaining of hematolymphoid marker such as LCA,L26,CD3,etc to assess diagnosis.
|
50 |
anonymous |
Lymphoma
|
perform hematolymphoid marker immunostaining of LCA, L26,CD3 etc...to assess diagnosis.
|
50 |
anonymous |
Haematolymphoid malignancy, 100%
|
Favour medium sized lymphoma
Immunostaining with CD3, CD20, MPO, Tdt
Immunostain for MNF116 to rule out carcinoma.
|
100 |
anonymous |
Hematolymphoid malignancy (with "blastoid" appearance)
|
Immunohistochemical studies to demonstrate lineage of the tumor cells e.g. blastoid mantle cell lymphoma, blastic plasmacytoid lymphoma, granulocytic sarcoma. Panel may include CD3, CD20, bcl-1, Myeloperoxidase, CD56, etc.
|
100 |
anonymous |
HEMATOLYMPHOID MALIGNANCY. Favor small cell lymphoma eg. maltoma. Other ddx: mantle cell lymphoma, B-CLL.
|
Other ddx, granulocytic sarcoma, T-cell lymphoma including gamma delta type. Remote ddx: invasive lobular carcinoma.
Do B and T markers, CD5/10/23, myeloperoxidase, CK.
Also to exclude primary elsewhere.
|
100 |
anonymous |
Myeloid sarcoma (granulocytic sarcoma) (100%)
|
nil
|
100 |
anonymous |
Breast - hematolymphoid neoplasm, favor granulocytic sarcom 100%
|
Special stain chloroacetate esterase for supporting diagnosis. Also to correlate with blood and marrow findings.
|
100 |
anonymous |
Malignant infiltrate 100%
|
Differential diagnosis includes invasive lobular carcinoma and malignant lymphoma. Immunostains for cytokeratin and LCA are useful to differentiate the two. The resection margin is involved.
|
50 |
anonymous |
Malignant tumour. DDx are haematolymphoid malignancy and lobular carcinoma
|
Immunohistochemical stains to differentiate the type of malignancy
|
50 |
anonymous |
Involved by Chronic lymphocytic leukemia / Small lymphocytic lymphoma.
|
nil
|
30 |
anonymous |
HAEMATOLYMPHOID NEOPLASM, favour medium sized lymphoma. Differential diagnosis includes myeloid sarcoma and low grade B cell lymphoma.
|
nil
|
100 |
anonymous |
Hematolymphoid malignancy (100%)
|
nil
|
30 |
anonymous |
Favor Haematolymphoid malignancy (including granulocytic/myeloid sarcoma) over small cell invasive lobular carcinoma 100%
|
In real life, one will always perform immunohistochemical study, starting with epithelial (cytokeratin) and lymphoid (LCA, CD3, CD20) markers, followed by E-cad and p120-catenin if cytokeratin positive and possible MPO (for positive diagnosis of granulocytic/myeloid sarcoma).
|
100 |
anonymous |
hematolymphoid malignancy, favor granulocytic sarcoma (100%)
|
Perform immunostaining to confirm the diagnosis and to rule out lymphoma and carcinoma: MPO, Tdt, CD3, CD20, cytokeratin
|
100 |
anonymous |
Breast: atypical lymphoid infiltration favors malignant lymphoma of small lymphoid cells, including small lymphocytic lymphoma (positive for CD23 and CD5), mantle cell lymphoma ( positive for cyclin D1), extranodal marginal cell lymphoma (negative for CD5, CD23, cyclin D1) and leukemic infiltration should also be ruled out (positive MPO) by performing relevant immunohistochemical stains. (100% probability)
|
nil
|
100 |
anonymous |
Lymphoid lesion. ? maltoma
|
nil
|
30 |
anonymous |
Malignant lymphoid infiltrate, consistent with low-grade lymphoma (90%)
Invasive lobular carcinoma (10%)
|
Confirm by performing CD3, CD20, MNF116 and E-Cadherin immunostains
|
50 |
anonymous |
Granulocytic sarcoma (70%), lymphoblastic lymphoma (30%)
|
Do immunohistochemistry myeloperoxidase to confirm granulocytic sarcoma; and TdT to confirm lymphoblastic lymphoma
|
100 |